Transforming Regenerative Medicine:
NurExone's Cutting-edge Exotherapy
What we’ll cover at the Event
Introduction to NurExone Biologic
An overview of NurExone Biologic, highlighting its mission, core focus on innovative biologic solutions, and groundbreaking contributions to regenerative medicine, with an emphasis on exosome-based therapeutics.
Pipeline & Development Progress
A detailed update on
NurExone's current pipeline, showcasing key assets, their stages of development, recent milestones achieved, and timelines for advancing through regulatory and
clinical pathways.
Market Landscape &
Competitive Edge
Insights from a Key Opinion Leader (KOL) on the unmet needs in the market, the competitive landscape, and how NurExone’s exosome-based solutions address
critical gaps, offering a vital approach to patient care.
Meet the Speakers
Lior Shaltiel
Dr Shaltiel is an entrepreneur and an award-winning scientist with extensive multidisciplinary international experience, specializing in chemical engineering, molecular biology, electrophysiology, pharmacology and drug delivery systems. Lior has years of experience in accelerating Israeli start-ups. Lior has worked in several nano-drug delivery companies such as LipoCure and Ayana Pharma.
Before joining NurExone, Lior was a VP and Partner at a boutique Chinese investment bank operating in Israel mapping the investment landscape and opportunities
in the Israeli pharmaceutical industry. Lior is the initiator and head of the BioMed-MBA program at the Hebrew University.
Leadership in Cutting-Edge Biopharmaceutical Innovation
Recognition in Medical Technology
Academic Expertise
Noa Avni
Noa Avni has diverse experience in various biotechnological domains. Noa independently led multiple projects at MeMed Diagnostics combining scientific, technological and industrial challenges in various product stages including product development, transfer to GMP manufacturing, and FDA approval processes of a novel multi-parametric immunoassay product and its integration with a novel Point-Of-Care measurement.
Noa also led various R&D, Bioanalytical and Preclinical activities at NanoGhost and Minovia Therapeutics- startups developing a novel drug delivery system based on Mesenchymal Stem Cells, and Mitochondrial therapies respectively.
Expertise in CNS-focused R&D
Pioneering Therapeutic Solutions
Contribution to Innovative Biotech Patents
Teodoro Forcht Dagi
Teodoro (Teo) Forcht Dagi is a neurosurgeon who serves as distinguished scholar and professor at Queen’s University Belfast and the William J. Clinton Leadership Institute. He also serves as international surgical advisor for the Royal College of Surgeons in Edinburgh, director of Life Sciences at Anglo Scientific at the Royal Institution of Great Britain, director of the American Association of Neurological Surgeons, and editor of Neurosurgery, the Journal of Clinical Ethics, and Humanities.
His research and teaching interests have focused on translational medicine, patient safety, digital health, head trauma and intracranial pressure measurement systems.
Academic and Clinical Leadership
Global Recognition
Industry Expertise
ABOUT US
Evolving Medical Ideologies & Technologies to Create Sustainable Alternatives to Modern Medicine
NurExone Biologic Inc. is a publicly-traded biopharmaceutical company, listed on the Toronto Stock Exchange (TSXV: NRX), the OTCQB Venture Market
(OTCQB:NRXBF) and Frankfurt Stock Exchange
(TSXV: NRX). Developing and commercializing the ExoTherapy platform for production of exosome-loaded nanodrugs.Nurexone is shaping the future of regenerative medicine.
COPYRIGHTS 2024 | TERMS & CONDITIONS